Ovation Science Full Year 2024 Earnings: CA$0.013 loss per share (vs CA$0.027 loss in FY 2023)

Simply Wall St

May 07, 2025

Ovation Science (CSE:OVAT) Full Year 2024 Results

Key Financial Results

Revenue: CA$113.2k (up 83% from FY 2023).
Net loss: CA$456.2k (loss narrowed by 44% from FY 2023).
CA$0.013 loss per share (improved from CA$0.027 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-history — CNSX:OVAT Earnings and Revenue History May 7th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ovation Science shares are down 25% from a week ago.

Risk Analysis

Be aware that Ovation Science is showing 5 warning signs in our investment analysis that you should know about...

If you're looking to trade Ovation Science, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.